Our results suggest that plasma fibrinogen is a useful biomarker for ruling out PJI in patients scheduled for this procedure, and it may be effective, when combined with CRP, for diagnosing PJI in such patients. This evidence concerns the gene CRP and juvenile polyposis syndrome.